Search results for "Staging."

showing 10 items of 715 documents

Prediction by quantitative histology of pathological stage in prostate cancer.

2005

To find a predictor of extraprostatic extension in clinically localized prostate cancer (PCa), pre-operative ultrasound-guided prostate needle biopsies and clinico-pathological data were reviewed.One hundred and eighty-three consecutive patients who underwent radical retropubic prostatectomy for clinical T1-T2 PCa and serum PSA10 ng/ml were reviewed. Pre-operative biopsy was performed according to an extended protocol and whole-mount prostatectomy specimens were processed. The following biopsy variables were categorized to this analysis: Gleason score (or =6,6), TPC (or =20%;20%), GPC (or =50%;50%), cancer-positive cores (or =2;2), cancer-positive cores in both lateral portions (yes; no), P…

Malemedicine.medical_specialtymedicine.medical_treatmentBiopsyUrologyurologic and male genital diseasesLogistic regressionSensitivity and SpecificityProstate cancerProstatePredictive Value of TestsBiopsymedicineOdds RatioHumansStage (cooking)AgedNeoplasm Stagingmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsGeneral MedicineOdds ratioMiddle AgedProstate-Specific Antigenmedicine.diseaseSurgerymedicine.anatomical_structureLogistic ModelsOncologyROC CurveMultivariate AnalysisSurgeryPositive Surgical MarginbusinessRadical retropubic prostatectomyEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer tre…

2015

Objectives To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). Patients and methods In a large retrospective multicentre cohort of 2451 patients with T1-HG/G3 initially treated with bacille Calmette–Gu erin, 935 (38%) had a re-TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re-TUR), group 2 (no muscle, re-TUR), group 3 (muscle, no re-TUR) and group 4 (muscle, re-TUR). Clinical out…

Malemedicine.medical_treatment030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineImmunologicRetrospective Studiehigh gradere-TURHazard ratioMiddle Agedmedicine.anatomical_structureAdministration IntravesicalTreatment Outcome030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]CohortUrinary Bladder NeoplasmBCG VaccineUrologic Surgical Proceduresbladder cancerFemaleHumanReoperationmedicine.medical_specialtyrecurrenceUrologyUrologyT1G3CystectomyArticleCystectomy03 medical and health sciencesbladder cancer; high grade; progression; re-TUR; recurrence; T1G3; UrologyAdjuvants ImmunologicUrethramedicineHumansAdjuvantsT1G3; bladder cancer; high grade; progression; re-TUR; recurrenceRetrospective StudiesAgedNeoplasm StagingBladder cancerbusiness.industryCancerRetrospective cohort studymedicine.diseaseSurgerybladder cancer; high grade; progression; re-TUR; recurrence; T1G3; Adjuvants Immunologic; Aged; BCG Vaccine; Cystectomy; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Reoperation; Retrospective Studies; Treatment Outcome; Urethra; Urinary Bladder Neoplasms; UrologyUrethraUrinary Bladder NeoplasmsprogressionNeoplasm GradingbusinessBCG vaccine
researchProduct

Prognostic Impact of Frozen Section Investigation and Extent of Proximal Safety Margin in Gastric Cancer Resection

2020

Background and aims Guidelines propose different extents of macroscopic proximal margin for gastric cancer and frozen margin investigation in selected cases, but data is lacking. This study was to evaluate the necessary extent of macroscopic proximal margin, accuracy of frozen margin investigation, and prognostic impact of tumor-free proximal margin length in pT2-pT4 gastric cancer. Study design Proximal and distal frozen margins were routinely investigated intraoperatively in all pT2-pT4 gastric cancers resected between 2011 and 2017. Macroscopic and microscopic proximal margin lengths were correlated. For R0-resections, survival analysis was performed for distal gastrectomy (DG) with micr…

Malemedicine.medical_treatmentCancer resection03 medical and health sciences0302 clinical medicineGastrectomyStomach NeoplasmsMargin (machine learning)medicineFrozen SectionsHumansSurvival analysisAgedNeoplasm StagingFrozen section procedureCentimeterbusiness.industryMargins of ExcisionCancerHistologyMiddle AgedPrognosismedicine.diseaseSurvival Analysis030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologySurgeryGastrectomyNuclear medicinebusinessAnnals of Surgery
researchProduct

The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer

2016

BACKGROUND Potential differences in efficacy of different bacillus Calmette-Guerin (BCG) strains are of importance for daily practice, especially in the era of BCG shortage. OBJECTIVE To retrospectively compare the outcome with BCG Connaught and BCG TICE in a large study cohort of pT1 high-grade non-muscle-invasive bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS Individual patient data were collected for 2,451 patients with primary T1G3 tumors from 23 centers who were treated with BCG for the first time between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Using Cox multivariable regression and adjusting for the most important prognostic factors in this nonrandomiz…

Malemedicine.medical_treatmentIntravesical drug administration030232 urology & nephrologyKaplan-Meier EstimateBCG ConnaughtSettore MED/24 - Urologia0302 clinical medicineMaintenance therapyMedicine610 Medicine & healthhigh gradeAged 80 and overHazard ratioMiddle AgedAdministration IntravesicalTreatment OutcomeOncology030220 oncology & carcinogenesisCohortbladder cancerFemaleImmunotherapyNon muscle invasivemedicine.medical_specialtyrecurrenceUrologyBCG Connaught; BCG Tice; BCG vaccine; bladder cancer; high grade; Immunotherapy; Intravesical drug administration; progression; recurrence; T1G3; Oncology; UrologyT1G3ArticleMaintenance ChemotherapyBCG Connaught03 medical and health sciencesAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]HumansNeoplasm InvasivenessBCG vaccineAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryImmunotherapy ActiveBCG TiceImmunotherapymedicine.diseaseSurgeryUrinary Bladder NeoplasmsDrug EvaluationprogressionNeoplasm GradingbusinessBCG vaccineFollow-Up StudiesBCG Connaught; BCG Tice; BCG vaccine; Immunotherapy; Intravesical drug administration; T1G3; bladder cancer; high grade; progression; recurrenceUrologic Oncology: Seminars and Original Investigations
researchProduct

Postoperative nomogram for invasive bladder cancer: does it really work? A multicenter cohort study.

2011

Objectives: Nomograms are statistical models designed to maximize predictive accuracy. We have tested the statistical correlation between the predictions of International Bladder Cancer Nomogram Consortium and the clinical outcomes in a multicenter Italian cohort of patients treated with radical cystectomy (RC) and pelvic lymph-nodes dissection. Methods and materials: Two hundred four patients who underwent RC were selected for multiple variable and then enrolled in the study. Patients were tested by the "online tool" based on the nomogram, then stratified and risk grouped for 5-year predicted disease-free survival (pDFS): low risk (67%-100%), intermediate risk (34%-66%), and high risk grou…

Malemedicine.medical_treatmentKaplan-Meier EstimatePostoperative nomogramNomogramCohort StudiesRetrospective StudieArea under curvePostoperative Periodinvasive bladder cancer; Postoperative nomogramAged 80 and overSettore MED/24 - UROLOGIAinvasive bladder cancerMiddle AgedPrognosisOncologyArea Under CurveUrinary Bladder NeoplasmCohortFemaleHumanCohort studyAdultmedicine.medical_specialtyPrognosiUrologyUrologyCystectomyDisease-Free SurvivalCystectomymedicineHumansAgedNeoplasm StagingRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryRetrospective cohort studyNomogrammedicine.diseaseRadical cystectomyNomogramsROC CurveUrinary Bladder NeoplasmsCohort StudieNeoplasm GradingPredictionbusinessStatistical correlationUrologic oncology
researchProduct

An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer

2018

PURPOSE: The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression. RESULTS: After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.8…

Malemedicine.medical_treatmentPrognosis.030232 urology & nephrologyComorbidityGastroenterologySettore MED/24 - Urologia0302 clinical medicineBladder cancer; Body mass index; Obesity; PrognosisMedicineBody mass indexAged 80 and overHazard ratioBladder cancerCystoscopyMiddle AgedPrognosisTumor BurdenAdministration IntravesicalEditorialTransitional cell carcinomaChemotherapy Adjuvant030220 oncology & carcinogenesisBCG VaccineDisease ProgressionFemalemedicine.medical_specialtyPrognosiUrologyCystectomyDisease-Free SurvivalCystectomy03 medical and health sciencesAdjuvants ImmunologicInternal medicineHumansObesityMortalityAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCancer stagingCarcinoma Transitional CellBladder cancer; Body mass index; Obesity; Prognosis; UrologyScience & TechnologyBladder cancerbusiness.industryProportional hazards modelmedicine.diseaseUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisbusinessBody mass index
researchProduct

Teratoma with a malignant somatic component in pediatric patients: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience

2010

BACKGROUND: Teratoma with a malignant somatic component (TMSC) is rare but described in adults, whereas information on pediatric presentation is sparse. PROCEDURE: The Associazione Italiana Ematologia Oncologia Pediatrica identified 14 cases of TMSC. Clinical files and pathology specimens were reviewed. RESULTS: The series (9 female, 5 male) showed the following disease: testis (2), sacrococcygeal (3), ovary (3), retroperitoneum (3), mediastinum (2), and foot soft tissue (1). Distribution of the somatic component was: carcinoma (4), pancreatic neuroendocrine tumor (1), neuroblastoma (3), rhabdomyosarcoma (3), rhabdomyosarcoma plus liposarcoma, chondrosarcoma, neurogenic sarcoma (1), chondro…

Malepediatric patientsAdolescentTeratoma; pediatric patientsSettore MED/20 - Chirurgia Pediatrica E InfantileInfant NewbornTeratomaInfantgerm cell tumorPrognosisSettore MED/38 - Pediatria Generale E SpecialisticaTreatment OutcomeItalyChild PreschoolSettore MED/20Humansmalignant trasformationFemaleChildchildhoodNeoplasm StagingRetrospective Studies
researchProduct

Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma.

2011

OBJECTIVES To investigate cancer-related outcomes and prognostic factors of papillary renal cell carcinoma (pRCC) in a large multicentre data set. Oncological outcome and prognostic factors of pRCC have been limitedly evaluated in comparison with the most common RCC subtype, clear cell RCC. PATIENTS AND METHODS From a multicentre retrospective database, including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007, 577 patients with pRCC were identified. Univariable and multivariable Cox regression models were performed to identify prognostic factors predictive of recurrence-free survival (RFS) and cancer-specific survival (CSS) after surge…

Malerenal cell carcinomaTime FactorsPapillary renal cell carcinoma; Prognostic factorsPrognosiFEATURESkidney cancer; papillaryrenal cell carcinoma; papillary adenocarcinoma; prognostic factorspapillary renal cell carcinomaNephrectomyCLASSIFICATIONFollow-Up Studiecancer-specific survivalpapillaryRisk FactorsRetrospective StudieCause of DeathPrevalenceHumansrecurrence-free survivalprognostic factorCarcinoma Renal CellTYPE-1Proportional Hazards ModelsRetrospective StudiesNeoplasm StagingAcademic Medical Centerspapillary adenocarcinomaRisk Factorkidney cancerKidney Neoplasmprognostic factorsMiddle AgedPrognosisTUMORSKidney NeoplasmsHISTOLOGIC SUBTYPESPrognostic factors in a large multi-institutional series of papillary renal cell carcinoma.Survival RateAcademic Medical CenterItalySURVIVALProportional Hazards ModelFemaleprognostic factors; papillary renal cell carcinoma; recurrence-free survival; cancer-specific survivalFollow-Up StudiesHuman
researchProduct

Elective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinoma: results of a retrospective, comp…

2012

Study Type - Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Few studies supported the expanded indications for nephron-sparing surgery (NSS) in selected patients with 4.1 cm renal tumours in the size range (T1b). However, all these comparative studies included both imperative and elective partial nephrectomy and patient selection for analysis was based on pathological stage (pT1) and not on clinical stage (cT1). Patients with clinically organ-confined RCC (cT1) who are candidates for elective PN have a limited risk of clinical understaging. NSS is not associated with an increased risk of recurrence and cancer-specific mortality both in cT1a a…

Malerenal cell carcinomapartial nephrectomyrenal cancerNephrectomymethodsElectiveclinical staging; nephron-sparing surgery; partial nephrectomy; radical nephrectomy; renal cancernephrectomyclinical stagingHumansCarcinoma Renal CellSurgical ProceduresElective Surgical ProcedureCarcinomanephron-sparing surgeryRenal CellElective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinomaKidney NeoplasmMiddle AgedKidney NeoplasmsSurvival Ratemortality/pathology/surgeryElective Surgical Proceduresnephrectomy; renal cell carcinoma; nephron-sparing surgeryFemaleCarcinoma; Renal Cell; mortality/pathology/surgery Female Humans Kidney Neoplasms; mortality/pathology/surgery Male Middle Aged Nephrectomy; methods Surgical Procedures; Elective Survival RateHumanradical nephrectomy
researchProduct

Whole-Body Magnetic Resonance Imaging: Current Role in Patients with Lymphoma.

2021

Imaging of lymphoma is based on the use of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) and/or contrast-enhanced CT, but concerns have been raised regarding radiation exposure related to imaging scans in patients with cancer, and its association with increased risk of secondary tumors in patients with lymphoma has been established. To date, lymphoproliferative disorders are among the most common indications to perform whole-body magnetic resonance imaging (MRI). Whole-body MRI is superior to contrast-enhanced CT for staging the disease, also being less dependent on histology if compared to 18F-FDG-PET/CT. As well, it does not require exposure to i…

Medicine (General)medicine.medical_specialtydiffusion-weighted imagingClinical BiochemistryWhole body imagingLymphoproliferative disorderslymphomaReviewwhole-body imaging030218 nuclear medicine & medical imagingIonizing radiation03 medical and health sciencesR5-9200302 clinical medicinehemic and lymphatic diseasesmedicinemagnetic resonance imagingmedicine.diagnostic_testbusiness.industryCancerMagnetic resonance imagingstagingmedicine.diseaseLymphomaPositron emission tomography030220 oncology & carcinogenesisRadiologybusinessDiffusion MRIDiagnostics (Basel, Switzerland)
researchProduct